Upon the invitation from Dr. Yu Dechao, Xinda Bio-pharmaceutical Chairman and CEO, Su Bing, Director of the Shanghai Institute of Immunology led the 6 people delegation visited Suzhou Xinda Biological Pharmaceutical Co., LTD. in the afternoon of January 27, 2016., , The delegation had a in-depth communication with the Dr. Yu DeChao, Chairman of Xinda, Drs. Liu Xiaolin, Sun Zuoyu, Liu Junjian, all Vice Presidents, and others to discuss about collaborations. PIs including Li Fubin, Huang Chuanxin, Li Yu and Vice Director Fang Lijuan accompanied on the visit.
Suzhou Xinda Biological Pharmaceuticals Co., Ltd. was founded by the China "Overseas High-level Talents" National Distinguished expert, Dr. Yu Dechao and other experts in bio-pharmaceutical industry in August 2011. It aims at becoming China's best, world-class pioneeringbio-pharmaceutical company to produce high-quality biological medicine that the Chinese people can afford, and has won the world's largest fund management company American Fidelity Investments (Fidelity), the world's top 500 companies Eli Lilly Pharmaceutical Group (Eli Lilly) Asian funds, Jun associated capital, Singapore's Temasek, Suzhou Yuan Wo capital and Tonghe capital’s joint venture. During the visit, Vice President Liu Xiaolin first introduced the bio-pharmaceutical company’s current status and future prospects. The company had obtained overseas capital of $232 million and itstotal investment would reach $232 million since then. Xinda Pharmacuticals had successfully established strategic cooperation with Fortune 500 company Eli Lilly in 2015. Currently, it has 10 kinds of proprietary monoclonal antibody drugs in development, which mainly cover cancer, diabetes and autoimmune diseases. Bio-pharmaceuticals is becoming a star of the pharmaceutical sector and benefits all patients. Innovative development of bio-pharmaceutical relies on the support from basic research. Thereforeit needs both sides’ effort to strengthen substantial development and establish win-win cooperation between Xinda and SII.
Director Su Bing introduced SII, China’s first institute specialized in immunological research. He presented SII’s milestone achievements in recent years, including personnel, infrastructure, research and distribution, medical enterprise cooperation and global exchanges. SII is particularly committed to tumor immunity, infection immunity, autoimmune diseases basic research with a cutting-edge and promising translation. Director Su Bing hoped to strengthen cooperation with bio-pharmaceutical companies to promote original research to be translated into the innovative drugs which can benefit patients. Principal Investigator Li Fubin, Huang Chuanxin and Li Yu discussed about their current research and progress intending to further promote cooperation. Especially Dr. Li Fubin has already started cooperation with Xinda. In the future, SII and Xinda bio-pharmaceutical company intend to cooperate in the field of cancer, autoimmune diseases to carry out the joint development of superior efficacy, high quality, low price of antibody drugs, and promote innovative development of high biological drugs, open a new model of cooperation between scientific research institutions and enterprises.
